Company intelligence / Profile preview

Salyx

Bridgewater, New Jersey, United Stateszoominfo.com ↗

Ownership: Private
Development stage: Other

Overview

Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies focused on gastroenterology. Its lead product, Xifaxan (rifaximin), is approved for hepatic encephalopathy and irritable bowel syndrome with diarrhea. Other key products address a range of gastrointestinal disorders including ulcerative colitis, chronic idiopathic constipation, opioid-induced constipation, and more. The company has a history of acquiring late-stage or marketed GI therapies.

Therapeutic areas: Gastroenterology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Photocure ASA ("Lumacan" colorectal diagnostic partnership)

Beyond the preview

Go deeper on Salyx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Salyx.

Explore the full profile